直接抗病毒治疗对慢性丙型肝炎合并物质使用障碍患者终末期肝病的影响
这项回顾性队列研究利用MarketScan数据库(2013-2018)纳入29228例慢性HCV患者,其中22%(n=6385)至少有一种物质使用障碍(SUD)诊断。采用逆概率治疗加权多变量Cox模型比较发生失代偿性肝硬化(DCC)和肝细胞癌(HCC)的风险,发现DAA治疗在非肝硬化SUD患者中降低DCC风险但不降低HCC风险,在肝硬化SUD患者中降低HCC风险但不降低DCC风险;未治疗的SUD患者DCC和HCC风险均显著高于无SUD者。
要点
- 非肝硬化HCV合并SUD者,DAA治疗降低DCC风险(aHR 0.13),但未降低HCC风险(aHR 0.91)。
- 肝硬化HCV合并SUD者,DAA治疗降低HCC风险(aHR 0.33),但未降低DCC风险(aHR 0.64)。
- 未治疗的SUD患者较无SUD者DCC和HCC风险更高,应推荐所有HCV合并SUD患者接受DAA治疗并处理SUD。
核心结论
- 在HCV合并SUD患者中,DAA治疗对非肝硬化者降低DCC风险但不降低HCC风险,对肝硬化者降低HCC风险但不降低DCC风险。
- 未治疗的SUD患者DCC和HCC风险显著高于无SUD者,应推荐所有HCV合并SUD患者接受DAA治疗并同时处理SUD。
研究设计与样本
- 回顾性队列研究,使用MarketScan数据库(2013-2018)纳入29228例慢性HCV患者,其中22%(n=6385)有至少一种SUD诊断。
- 采用逆概率治疗加权多变量Cox比例风险模型比较DCC和HCC风险。
主要发现
- 非肝硬化患者中,DAA治疗降低SUD组DCC风险(aHR 0.13;95% CI 0.06-0.30)和非SUD组DCC风险(aHR 0.11;95% CI 0.07-0.18)。
- 非肝硬化SUD组中,DAA治疗未降低HCC风险(aHR 0.91;95% CI 0.33-2.48)。
- 肝硬化患者中,DAA治疗降低SUD组HCC风险(aHR 0.33;95% CI 0.13-0.88)和非SUD组HCC风险(aHR 0.40;95% CI 0.25-0.65)。
- 肝硬化SUD组中,DAA治疗未降低DCC风险(aHR 0.64;95% CI 0.37-1.13)。
- 未治疗的肝硬化患者中,SUD组较非SUD组DCC风险更高(aHR 1.52;95% CI 1.03-2.24),HCC风险也更高(aHR 1.69;95% CI 1.05-2.72)。
临床怎么用
- 对所有慢性HCV合并SUD患者应考虑DAA治疗,同时针对SUD进行干预。
- 非肝硬化HCV合并SUD患者经DAA治疗后仍需关注HCC风险,肝硬化SUD患者经DAA治疗后仍需关注DCC风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Our aim was to evaluate the impact of direct-acting antivirals (DAAs) on decompensated cirrhosis (DCC) and HCC in patients with chronic HCV and substance use disorder (SUD) compared with those without an SUD. APPROACH AND RESULTS: This retrospective cohort study used the MarketScan database (2013-2018) to identify 29,228 patients with chronic HCV, where 22% (n = 6,385) had ≥1 SUD diagnosis. The inverse probability of treatment weighted multivariable Cox proportional hazard models were used to compare the risk of developing DCC and HCC. Among the those who were noncirrhotic, treatment reduced the DCC risk among SUD (adjusted hazard ratio [aHR] 0.13; 95% CI, 0.06-0.30) and non-SUD (aHR 0.11; 95% CI, 0.07-0.18), whereas the risk for HCC was not reduced for the SUD group (aHR 0.91; 95% CI, 0.33-2.48). For those with cirrhosis, compared with patients who were untreated, treatment reduced the HCC risk among SUD (aHR, 0.33; 95% CI, 0.13-0.88) and non-SUD (aHR, 0.40; 95% CI, 0.25-0.65), whereas the risk for DCC was not reduced for the SUD group (aHR, 0.64; 95% CI, 0.37-1.13). Among patients with cirrhosis who were untreated, the SUD group had a higher risk of DCC (aHR, 1.52; 95% CI, 1.03-2.24) and HCC (aHR, 1.69; 95% CI, 1.05-2.72) compared with non-SUD group. CONCLUSIONS: Among the HCV SUD group, DAA treatment reduced the risk of DCC but not HCC for those who were noncirrhotic, whereas DAA treatment reduced the risk of HCC but not DCC for those with cirrhosis. Among the nontreated, patients with an SUD had a significantly higher risk of DCC and HCC compared with those without an SUD. Thus, DAA treatment should be considered for all patients with HCV and an SUD while also addressing the SUD.
引用
- Park H, Jiang X, Song HJ, et al. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. Hepatology. 2021. PMID: 33544904. doi:10.1002/hep.31732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。